Dunn-Pirio Anastasie M, Shah Suma, Eckstein Christopher
Department of Neurology, Duke University, Durham, North Carolina, USA.
Case Rep Oncol. 2018 Jul 27;11(2):521-526. doi: 10.1159/000491599. eCollection 2018 May-Aug.
Recently, immune checkpoint inhibitors have revolutionized cancer care by enhancing anti-tumor immunity. However, by virtue of stimulating the immune system, they can lead to immune-related adverse events (irAEs). Neurologic irAEs are uncommon but are becoming increasingly recognized and can be quite serious or even fatal. Furthermore, central nervous system (CNS) manifestations may be difficult to distinguish from CNS metastases, posing management challenges. Here, we describe a patient who developed exacerbation of sarcoidosis leading to CNS involvement following dual checkpoint blockade with nivolumab and ipilimumab for metastatic melanoma and review the relevant literature.
最近，免疫检查点抑制剂通过增强抗肿瘤免疫力彻底改变了癌症治疗方式。然而，由于刺激免疫系统，它们可导致免疫相关不良事件（irAE）。神经系统irAE并不常见，但越来越受到关注，且可能相当严重甚至致命。此外，中枢神经系统（CNS）表现可能难以与CNS转移瘤相区分，给治疗带来挑战。在此，我们描述一名在接受纳武单抗和伊匹单抗双重检查点阻断治疗转移性黑色素瘤后发生结节病加重并累及CNS的患者，并回顾相关文献。
